MYCN and neuroblastoma: While mutational burden in these tumors is low, MYCN amplified neuroblastomas and medulloblastoma often exhibit large copy number alterations, most notably 17q gain2,3, indicating that additional gene dosage effects are required to support tumor initiation and/or progression.